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Improving the Primary Prevention
of Cardiovascular Events by Using Biomarkers
to Identify Individuals With Silent Heart Disease
M. Adnan Nadir, MD,* Sushma Rekhraj, MB,* Li Wei, PHD,† Tiong K. Lim, MD,* John Davidson, MB,‡
Thomas M. MacDonald, MD,† Chim C. Lang, MD,* Ellie Dow, PHD,§ Allan D. Struthers, MD*
Dundee, United Kingdom
Objectives The aim of this study was to examine whether biomarkers can identify silent cardiac target organ damage
(cTOD) in a primary prevention population.
Background One possible way to improve primary prevention of cardiovascular events is to identify those patients who al-
ready harbor silent cTOD (i.e., myocardial ischemia, left ventricular hypertrophy, systolic dysfunction, diastolic
dysfunction, or left atrial enlargement). This might be possible by screening with a biomarker (e.g. high sensitiv-
ity cardiac troponin T [hs-cTnT] or B-type natriuretic peptide [BNP]).
Methods We prospectively recruited 300 asymptomatic individuals already receiving primary prevention therapy. Trans-
thoracic echocardiography, stress echocardiography, and/or myocardial perfusion imaging were performed to
identify silent cTOD.
Results One hundred two (34%) patients had evidence of cTOD. Left ventricular hypertrophy was the most prevalent
(29.7%) form of cTOD, followed by diastolic dysfunction (21.3%), left atrial enlargement (15.3%), systolic dys-
function (6.3%), and ischemia (6.3%). The area under the curve (AUC) for BNP to identify any form of silent cTOD
was 0.78 overall and 0.82 in men. The equivalent figures for hs-cTnT were 0.70 and 0.75 in women. The AUC for
BNP and hs-cTnT together was 0.81 and 0.82 in men. However, the discrimination power of other markers was
poor, with AUCs of 0.61 for microalbuminuria, 0.49 for uric acid, and 0.58 for eGFR.
Conclusions In asymptomatic treated primary prevention patients, BNP screening is able to identify existing silent cTOD. The
performance of hs-cTnT was not as good as that of BNP. B-type natriuretic peptide plus hs-cTnT together per-
formed best. Prescreening with BNP  cTnT followed by targeted phenotyping is worth exploring further as a
possible way to improve primary prevention. (J Am Coll Cardiol 2012;60:960–8) © 2012 by the American
College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.04.049The primary prevention of cardiovascular (CV) events has
achieved a great deal, but there is much room for further
improvement. In practice, primary prevention focuses on
achieving target levels of longstanding risk factors such as
blood pressure (BP) and cholesterol and then awaiting new
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accepted April 16, 2012.symptoms due to overt heart disease. The inadequacy of this
current approach can be illustrated in 3 ways. First, CV
events are still the most common cause of hospitalizations
and death. Second, it has been estimated that 43% of
coronary events would still occur even if we achieved perfect
risk factor control (1). Third, 40% to 50% of sudden cardiac
deaths (SCDs) occur in individuals before they have ever
developed overt heart disease (2). In fact, during the 50- to
59-year decade, 1% of all men suffer an SCD before ever
developing overt heart disease (2).
See page 969
Those who die suddenly with no overt heart disease do,
however, often have silent cardiac target organ damage
(cTOD). For example, patients with silent ischemia are
known to have a 21-fold increase in risk of a coronary event
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utopsy finding in cases of SCD (4). However, we not only
ant to reduce SCDs; we also want to better prevent nonfatal
V events, and silent ischemia is not the only predictor of
onfatal events. Tsang et al. (5) have also shown that echocar-
iographic abnormalities like left ventricular hypertrophy
LVH), left ventricular systolic dysfunction (LVSD), left ven-
ricular diastolic dysfunction (LVDD), and left atrial enlarge-
ent (LAE) each independently predict CV events (hazard
atios of 1.42 to 1.70] (5–8).
Yet the key weakness in current primary prevention is
hat it is not standard practice to investigate primary
revention patients to identify silent cTOD, because “phe-
otyping” all primary prevention patients would be prohib-
tively expensive. What might reduce the costs of pheno-
yping would be if treated primary prevention patients could
e pre-screened with a biomarker that identifies those
atients most likely to be harboring silent cTOD and
hereafter to target only them for detailed cardiac pheno-
yping. There are several potential biomarkers for this—
-type natriuretic peptide (BNP), high-sensitivity cardiac tro-
onin T (hs-cTnT), microalbuminuria, estimated glomerular
ltration rate (eGFR), uric acid, or some combination of these.
herefore, we set out to see how well each biomarker would
dentify cTOD in a population of treated primary prevention
atients. If positive, this could validate a possible way forward
o improve primary prevention, by using a screening biomarker
o select patients for cardiac phenotyping.
ethods
tudy population. This was a cross-sectional study. The
ubjects in this study were randomly recruited between April
008 and July 2010 from local general practitioner surgeries
nd from the CV risk clinic at Ninewells Hospital, Dundee,
nited Kingdom. In sampling from both sources, random
uitable patients were written to so that the populations
ecruited were unbiased from within each source. From the
ist of those who responded to the initial invitation, recruit-
ent was from consecutive patients. The response rate was
2%, and there were no major differences in the character-
stics of the 2 cohorts or the overall results. Patients were
uitable if they were 50 years of age or above and eligible for
rimary prevention only with no previous known CV
isease. They had to be stable on therapy for at least1 year
nd to have reached target for their primary risk factor (e.g.,
ffice BP 140/90 mm Hg or 25% reduction in total
holesterol) (9). We excluded those with previously known
V disease, known renal impairment (eGFR 60 ml/min),
trial fibrillation, and significant (defined as more than
ild) valvular heart disease either on auscultation or echo-
ardiography. All study subjects underwent clinical assess-
ent, biochemical measurements (including BNP, hs-
TnT, and urinary microalbumin), electrocardiography
ECG), transthoracic echocardiography, dobutamine stress
chocardiography (DSE) to detect myocardial ischemia, and4-h ambulatory BP measure-
ent (Spacelab Healthcare, Is-
aquah, Washington).
iochemical assays. Biochemical
easurements including BNP and
s-cTnT were made by trained lab-
ratory staff blinded to clinical and
chocardiographic data. The BNP
as measured with Triage BNP as-
ay (Biosite, Inc., San Diego, Cali-
ornia), whereas hs-cTnT was mea-
ured with a highly sensitive assay on
n automated platform (Elecsys
170, Roche Diagnostics, Basel,
witzerland) with a lower limit of
etection of 3 ng/l. Microalbumin-
ria was defined as urinary albumin/
reatinine ratio of 30 mg/g, mea-
ured on a spot urine sample,
hereas eGFR was calculated with
odification of Diet in Renal Dis-
ase formula.
maging procedures. A com-
rehensive echocardiogram was
erformed in each individual in-
luding M-mode, 2-dimensional,
olor, and tissue Doppler imag-
ng. All echocardiograms were
erformed by a single trained
perator (M.A.N.) with the same
chocardiographic instrument (Philips iE33, Philips Healthcare,
ndover, Massachusetts) according to a standardized protocol
ased on the recommendations by the American Society of
chocardiography (10). The operator was blinded to the
iochemical data, including BNP and hs-cTnT. LVH was
efined as left ventricular (LV) mass index 95 g/m2 in
women and LV mass index 115 g/m2 in men as per the
agreed American Society of Echocardiography criteria (10).
Left atrial volume (LAV) was calculated with ellipsoid
formula, and an LAV index of 28 ml/m2 was used to
define LAE. Left ventricular systolic dysfunction was de-
fined as (modified Simpson’s rule) EF 50%, and LVDD
was defined as mitral (lateral annulus) E/e’ of 15. Those
with a borderline E/e’ (9–15) were considered to have
LVDD if they also had an enlarged left atrium as suggested
(11). Interobserver and intraobserver agreements for echo-
cardiographic measures were performed by re-analyzing
echocardiographic images of randomly selected study sub-
jects. With alpha model reliability analysis, we calculated
intra-class correlation coefficient with a 95% confidence
interval (CI). The intraclass correlation coefficient for
M-mode, 2-dimensional, and Doppler imaging ranged
between 0.93 and 0.98 for the intraobserver variability and
between 0.92 and 0.96 for the inter-observer variability. The
presence of myocardial ischemia was primarily assessed by
Abbreviations
and Acronyms
AUC  area under the
curve
BNP  B-type natriuretic
peptide
BP  blood pressure
cTOD  cardiac target
organ damage
CV  cardiovascular
DSE  dobutamine stress
echocardiography
ECG  electrocardiography
eGFR  estimated
glomerular filtration rate
hs-cTnT  high-sensitivity
cardiac troponin T
LAE  left atrial
enlargement
LVDD  left ventricular
diastolic dysfunction
LVH  left ventricular
hypertrophy
LVSD  left ventricular
systolic dysfunction
ROC  receiver-operating
characteristic
SCD  sudden cardiac
deathDSE according to a standard protocol (12). A 16-segment
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abnormalities of 1 LV segment were considered as indic-
ative of inducible ischemia. Those patients where DSE was
inconclusive for technical reasons underwent tetrofosmin
myocardial perfusion scanning. Dipyridamole was used as
the stressor with gated single-photon emission computed
tomography analysis.
Statistical methods. Continuous variables are reported as
median (interquartile range [IQR]), and categorical vari-
ables are reported as proportions. Characteristics of patients
with or without cTOD were compared (Table 1) by the
chi-square test for categorical variables and by the Student t
test or Mann-Whitney U test for continuous variables as
ppropriate. The biomarkers were analyzed as continuous as
Characteristics of the Study PopulationTable 1 Characteristics of the Study Popula
All
Variables (n  300)
Age (yrs) 64.4 6.2
Male 175 (58)
Hypertension 269 (89)
Dyslipidemia 178 (59)
Diabetes mellitus 18 (6)
Current smokers 55 (18)
Ex-smokers 43 (14)
Body mass index (kg/m2) 28 4.1
Ambulatory SBP (mm Hg) 120 (112–128)
Ambulatory DBP (mm Hg) 72 (67–77)
Pharmacotherapy
Antiplatelets 63 (21)
ACE inhibitors 120 (40)
Angiotensin-receptor blocker 83 (28)
Beta-blockers 57 (19)
Calcium-channel blocker 117 (39)
Thiazides 129 (43)
Others antihypertensives 41 (14)
Statins 165 (55)
Cholesterol (mmol/l) 4.9 (4.1–5.6)
HDL (mmol/l) 1.4 (1.1–1.7)
Creatinine (mol/l) 76 17
eGFR (ml/min) 84 (76–94)
BNP (pg/ml) 14.7 (8.1–26.1)
hs-cTnT (ng/l) 4.4 (3.0–6.9)
UACR (mg/g) 11.4 (5.3–23.1)
Uric Acid (mol/l) 434 101
12 lead ECG
Normal 125 (42)
Minor abnormalities 110 (37)
Major abnormalities 62 (21)
LV mass index (g/m2) 106 25
LV EF (%) 60 6
LAV index (ml/m2) 23 (7)
E/e’ 11 3
Values are mean  SD, n (%), or median (interquartile range). *Comp
by chi-square test for categorical variables and by the Student t test o
ACE  angiotensin-converting enzyme; BNP  B-type natriuretic pe
ECG  electrocardiography; E/e’  transmitral early velocity/annu
estimated glomerular filtration rate; HDL  high-density lipoproteins; hs-c
LV  left ventricular; SBP  systolic blood pressure; UACR  urinary albuminwell as ordered categorical variables. Receiver-operating
characteristic (ROC) curves were constructed for the bio-
markers to assess their ability to identify presence or absence
of cTOD as a primary outcome measure. The area under the
ROC curves was compared by a nonparametric approach.
The incremental value of combining various biomarkers was
calculated by multivariate logistic regression. We also di-
vided the study cohort into tertiles on the basis of BNP
levels according to a pre-specified protocol. This tertile
approach has previously been taken by the Framingham
Heart Study group (13), and we pre-specified this tertile-
based analysis at the time of study conception. The signif-
icance level for the trend across the tertiles was calculated by
Jonckheere-Terpstra test and chi-square test. A similar
o cTOD cTOD
Significance*n  198) (n  102)
3.4 5.9 66.2 6.1 0.001
119 (60) 56 (55) 0.38
175 (88) 94 (92) 0.31
119 (60) 59 (58) 0.70
11 (6) 7 (7) 0.65
35 (18) 20 (19) 0.64
31 (16) 12 (12) 0.63
8 3.8 28 4.4 0.35
(111–127) 122 (113–128) 0.12
1 (67–77) 70 (66–76) 0.18
40 (20) 23 (22) 0.65
85 (43) 35 (34) 0.15
48 (24) 35 (34) 0.06
30 (15) 27 (26) 0.02
75 (38) 42 (41) 0.57
77 (39) 52 (51) 0.04
21 (11) 20 (19) 0.03
116 (58) 49 (48) 0.08
(4.2–5.7) 4.8 (4.1–5.6) 0.66
(1.1–1.6) 1.5 (1.1–1.8) 0.48
75 17 78 17 0.24
(76–100) 82 (71–99) 0.009
(6.3–18.8) 25.4 (15.6–42.4) 0.001
2 (3.0–5.9) 5.9 (3.9–8.9) 0.001
(4.8–19.9) 14.3 (7.5–35.1) 0.003
35 96 440 101 0.96
97 (49) 28 (27) 0.001
64 (32) 46 (45) 0.03
34 (17) 28 (27) 0.04
94 15 128 25 0.001
62 5 57 7 0.001
21 (4) 28 (9) 0.001
10 2 13 4 0.001
f study subjects with or without cardiac target organ damage (cTOD),
-Whitney U test for continuous variables.
TOD  cardiac target organ damage; DBP  diastolic blood pressure;
ue Doppler early velocity ratio; EF  ejection fraction; eGFR tion
N
(
6
2
118
7
4.9
1.4
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10.6
3.7
9.8
4
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ptide; c
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/creatinine ratio.
w
i
T
s
i
s
L
l
1
p
s
R
P
c
t
3
t
d
1
i
l
m
(
(
3
o
u
s
B
963JACC Vol. 60, No. 11, 2012 Nadir et al.
September 11, 2012:960–8 Biomarkers and Silent Cardiac Target Organ Damageanalysis was performed for hs-cTnT. All statistical analyses
were performed with SPSS for Windows (version 16.0,
SPSS, Chicago, Illinois), and a 2-sided p value of 0.05
as considered to be significant. The net reclassification
ndex was calculated as described by Pencina et al. (14). The
ayside Research and Ethics Committee approved the re-
earch protocol, and all study participants provided written
nformed consent. Power calculations at the outset by our
tatistician suggested we needed 83/tertile to detect an 8%
VH prevalence in the low BNP tertile versus a 30% preva-
ence in the high tertile. We rounded these figures up to
00/tertile. We assessed the 2 cohorts (hospital and general
ractitioner) separately, but both results were essentially the
ame.
esults
revalence of cTOD. A total of 300 patients were in-
luded in this study (Table 1). They had been receiving
herapy for their primary risk factor for a mean duration of
.3  2.8 years (40.7% treated hypertensives, 49% both
reated hypertension and dyslipidemia, and 10.3% treated
yslipidemia only). Ultrasound contrast agent was used in
1% of patients, and myocardial perfusion scans were used
n 7%. A total of 102 (34%) participants had evidence of at
east 1 form of cTOD. Left ventricular hypertrophy was the
ost prevalent (29.7%) form of cTOD, followed by LVDD
21.3%), LAE (15.3%), LVSD (6.3%), and ischemia
6.3%). Of those with cTOD, 29% had 1 form of cTOD,
1% had 2 forms, 29% had 3, and 10% had 4 or more forms
f cTOD. Only 1 patient had evidence of a previous
nrecognized myocardial infarction and no patients had any
ignificant right ventricular abnormalities.
NP and cTOD. The BNP levels were significantly
higher (median: 25.4 [IQR: 15.6 to 42.4] pg/ml vs. 10.6
[IQR: 6.3 to 18.8] pg/ml, p  0.001) in those with cTOD
compared with those without (Fig. 1A). In a multivariate
logistic model that included age, sex, body mass index, and
eGFR, BNP (p  0.001) remained an independent predic-
tor of underlying cTOD. A 1-SD rise in log BNP was
associated with an increased risk of existing cTOD (adjusted
odds ratio: 3.3, 95% CI: 2.3 to 4.7). Moreover, BNP levels
were higher in those who had multiple (2) forms of
cTOD compared with those who had a single form of
cTOD (median: 33.2 [IQR: 19.2 to 56.1] pg/ml vs. 15.8
[IQR: 10.8 to 23.5] pg/ml, p  0.001) (Fig. 2). The AUC
for BNP to identify any form of cTOD was 0.78 (95% CI:
0.73 to 0.83, p  0.001). We re-calculated the AUC after
BNP was adjusted for age, sex, eGFR, and body mass index,
but no significant change in the AUC (p  0.198) was noted.
We also recalculated the AUC for BNP by stratifying study
population by age groups. The AUC was better (0.82 vs. 0.77)
among those younger than 60 years compared with those60
years old. The BNP also seemed to perform better in men
(Tables 2 and 3). When divided into tertiles, the prevalence ofeach cTOD significantly (p  0.001) increased from the
bottom BNP tertile to the top BNP tertile (Fig. 1A).
hs-cTnT and cTOD. Similarly, hs-cTnT levels were sig-
nificantly higher (median: 5.91 [IQR: 3.97 to 8.95] ng/l vs.
3.72 [IQR: 3.00 to 5.93] ng/l, p  0.001) in those with
cTOD compared with those without. In multivariate logis-
tic analysis, after correcting for age, sex, and eGFR, hs-
cTnT (p  0.001) remained an independent predictor of
existing underlying cTOD. A 1-SD rise in logarithmically
transformed hs-cTnT was associated with an increased risk
of existing cTOD (adjusted odds ratio: 2.1, 95% CI: 1.55 to
2.82). The AUC for hs-cTnT to identify any form of
cTOD was 0.70 (95% CI: 0.63 to 0.76, p  0.001). When
divided into tertiles, the prevalence of each cTOD (except
LVSD) increased significantly from the bottom hs-cTnT
tertile to the top hs-cTnT tertile (Fig. 1B).
Microalbuminuria, eGFR, uric acid, and cTOD. Mi-
croalbuminuria (defined as urinary albumin/creatinine ratio
of 30 mg/g) was an independent predictor of cTOD, but
its AUC was only 0.61. Similarly, both uric acid and eGFR
had poor discriminating power, with AUC 0.49 (p  0.43)
and 0.58 (p  0.02), respectively (Table 3).
12-lead ECG and cTOD. We classified ECG as normal,
minor abnormalities, and major abnormalities as described
by Davie et al. (15). In our study, neither ECG parameter
performed well (Table 3). Clinical prediction scores (Fra-
mingham, QRISK, and ASSIGN) also performed poorly
(AUCs of 0.60, 0.51, and 0.62), but their performance was
greatly enhanced by adding BNP (Table 4). The net
reclassification index was 11% for BNP alone and 12.3% for
BNP plus hs-cTnT in comparison with Framingham.
When BNP and hs-cTnT were combined, the AUC was
0.81, and the number of missed cases was low (Table 5).
Discussion
We have found that BNP screening of treated primary
prevention patients is an effective way to identify which
treated primary prevention patients are already harboring
silent cTOD. Its test-performing characteristics are similar
to other commonly used screening tests, including prostate-
specific antigen (PSA) for prostatic cancer (AUC 0.68 to
0.78), mammography for breast cancer (AUC 0.78), and
pap smears for cervical cancer (AUC 0.74) (16–18). The
performance of hs-cTnT was not as good as BNP and the
other biomarkers, but the combination of BNP and hs-
cTnT was best.
Previous work in various different populations had already
shown that BNP could identify 1 or 2 isolated abnormalities
like LVH, LAE, and LV dysfunction and silent ischemia
(19–23). However, it is worth emphasizing the novelty and
importance of this study. Firstly, no previous BNP study
had looked so comprehensively at all of these forms of
cTOD in the 1 study. This is very important, because
patients harboring forms of cTOD not assessed in prior
studies will appear as false positives for BNP unless the
ib
w
p
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likely to be the comprehensive nature of our cTOD pheno-
typing in this study that has led to our AUCs being so good
and in particular to our key observation that BNP is at least
doubled when more than 1 form of cTOD exists. Secondly,
all diagnostic and screening tests perform differently in
different populations, and no previous study had examined
(treated) primary prevention patients. Thirdly, we were able to
directly compare BNP and hs-cTnT in a single population,
A
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tiles and cardiac target organ damage. The distribution of various forms of car
Tertile II hs-cTnT 3.3 to 5.92 ng/l, and Tertile III hs-cTnT 5.93 to 21.5 ng/l). *
ventricular diastolic dysfunction (LVDD), and left ventricular hypertrophy (LVH).
p  NS.and no previous publication has compared both biomarkers in bthe 1 population. However, the main and unique importance
of this work is that we have now validated a possible new way
forward (BNP cTnT screening and selected phenotyping) to
mprove the primary prevention of CV events.
In our study, BNP performed better in men, as seen
efore (24). Also, hs-cTnT levels were closely associated
ith LV mass and LA volume, which is in line with
reviously published data from a general population (25).
It is intriguing that in the published data, novel plasma
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cance level for trend across the tertiles for atrial enlargement (LAE), left
schemia, p  0.04; and for left ventricular systolic dysfunction (LVSD),7%
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tional risk factors (26). Our suggested approach is BNP
followed by targeted phenotyping, and this is very different
from using BNP on its own, because the patients who would
be regarded as being at high risk by our suggested approach
would have had to fail both a biomarker test and specific
investigations for cTOD. Furthermore, another major ben-
efit of our suggested approach is that the intensified treat-
ment in each patient could be targeted toward the exact
form of cTOD found in that individual (i.e., personalized
medicine) and not just to some generally increased risk
identified by a biomarker, which by itself does not indicate
the source of the high risk.
This does beg the question of what additional therapies
the identification of cTOD might lead to. For silent
ischemia, additional therapies could be beta blockade, aspi-
rin, and statins: neither aspirin nor beta-blockade are
routinely recommended for primary prevention per se (beta
blockers have been relegated to 4th line antihypertensives),
and statins are only used in a proportion. One study did
suggest that such an anti-ischemic regime could reduce
events by 80% in silent ischemia (27). It could even lead to
coronary angioplasty in selected cases, where 2 studies in
silent ischemia have produced impressive results (28,29). As
to the finding of normotensive LVH, new treatments could
be extra BP reduction, allopurinol or copper chelation, or
even the preferential use of ARBs or aldosterone antago-
nists, because they have a better evidence base that they are
effective at regressing LVH (30–34). As to the finding of
LVSD, the addition of beta blockers, angiotensin-
Figure 2 BNP and Cardiac Target Organ Damage
B-type natriuretic peptide (BNP) levels (mean, pg/ml) in those with the worst
forms of cardiac target organ damage (cTOD) (silent ischemia, left ventricular
systolic dysfunction [LVSD], 2 cTODs, 3 cTODs) in comparison with normal or
those with 1 cTOD only.converting enzyme inhibitors, and aldosterone antagonistsin combination could markedly reduce risk, possibly by 40%
to 50% according to the trials in early heart failure. We
deliberately focused on the cardiac abnormalities that are
known to be harmful rather than just those known to be
currently treatable, because future treatments are bound to
be developed. For example, the TOPCAT (Trial of Aldo-
sterone Antagonist Therapy in Adults With Preserved
Ejection Fraction Congestive Heart Failure) study might
endorse spironolactone for LVDD. Left atrial dilation
predicts atrial fibrillation, and in the future we might be able
to use aldosterone blockade to prevent atrial fibrillation
developing, as occurred in the EMPHASIS-HF (Epler-
enone in Mild Patients Hospitalization and Survival Study
in Heart Failure) study.
It is obviously important to consider the possible cost-
effectiveness of BNP screening followed by targeted pheno-
typing. It is worth emphasizing that the phenotyping only
involves a baseline echo and a stress echo that could be done
in 1 session. Furthermore, all the drug interventions pro-
posed in the preceding text are cheap, nongeneric drugs. In
this analysis, we have to focus on the top BNP tertile only
group, because it is only for this group that we have detailed
information on outcomes, from Paget et al. (35). A rough
calculation for 300 patients might be £3,000 ($4,500 USD)
for 300 BNPs, £2,0000 ($3,000 USD) for approximately
100 echocardiograms using published costs, and £70/year
($105/year USD) for aspirin, and so forth—in the patients
who fail both the BNP test and the echocardiogram test
(36). In terms of effect, we would expect 8 deaths over 7
years in our top tertile (35). If we assume our treatment
reduces those by 25% (and the SWISS I study [Swiss Inter-
ventional Study on Silent Ischemia type I] suggests it could be
up to 80% for some patients), then we could expect to save 2
lives in 7 years. Overall this would mean that each life saved
costs approximately £25,000 ($37,500 USD) over 7 years (i.e.,
£3,500/year [$5,250/year USD]). If extended to 11 years, the
cost would be less for each life saved (i.e., £19,111 [$28,666
USD] each or £1,737/year [$2,605/year USD]). Of course this
analysis only addresses total deaths and not the nonfatal CV
events that our strategy is likely to also reduce. Fewer nonfatal
CV events could also lead ultimately to fewer hospital stays for
heart failure and chest pain, which will also enhance the
cost-effectiveness of this approach.
Even without further targeting to specific patient subgroups,
it seems that BNP overall is a little better at screening than
PSA. At a level of 1.1 ng/ml, PSA is 83% sensitive and only
39% specific, whereas at 3.1 ng/ml, it is 32% sensitive and 86%
specific. If these PSA figures are compared with BNP cutoffs
of 10 and 30 pg/ml, BNP outperforms PSA as a screening test
(Table 2). The PSA is probably the best comparator for BNP,
because both are continuous variables. The reason PSA has not
been adopted is not because PSA is a poor screening test but
rather because prostate cancer can behave benignly, whereas its
treatments are fairly invasive.
We would not be rigid, from these data, on which exact
group should be phenotyped (e.g., the top BNP tertile
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pg/ml or a cTnT 5.93 ng/l or some other group). Further
larger studies should address which exact cohort should be
phenotyped. Another key issue is the number of cTOD cases
missed by any cutoff, and it is clear from Table 5 that we would
nly miss 13% of cTOD cases if we used 1 of the best-
erforming cutoffs (BNP 15 pg/ml or cTnT 5.93 ng/l).
owever, even this figure overstates its significance, because
he cases missed are seldom the more serious cases, (i.e., those
ith LVSD or silent ischemia or 2 forms of cTOD are very
Test Performing Characteristics of BNP, hs-cTnT, and Their CombinTable 2 Test Performing Characteristics of BNP, hs-cTnT, and
Test Cutoff Sex Sensitivi
BNP 10 pg/ml
n  183
Overall 85%
Men 84%
Women 89%
BNP 15 pg/ml
n  141
Overall 72%
Men 73%
Women 80%
BNP 20 pg/ml
n  102
Overall 58%
Men 61%
Women 59%
BNP 30 pg/ml
n  51
Overall 34%
Men 42%
Women 37%
hs-cTnT 4 ng/l
(Median)
n  165
Overall 74%
Men 76%
Women 71%
hs-cTnT 5.93 ng/l
(Top Tertile)
n  100
Overall 50%
Men 63%
Women 34%
BNP or hs-cTnT 15 pg/ml or
4 ng/l
n  219
Overall 92%
Men 91%
Women 93%
BNP and hs-cTnT 15 pg/ml and
4 ng/l
n  94
Overall 68%
Men 67%
Women 69%
BNP or hs-cTnT 20 pg/ml or
4 ng/l
n  195
Overall 86%
Men 88%
Women 85%
BNP and hs-cTnT 20 pg/ml and
4 ng/l
n  88
Overall 58%
Men 63%
Women 58%
BNP or hs-cTnT 15 pg/ml or
5.93 ng/l
n  171
Overall 87%
Men 88%
Women 85%
BNP and hs-cTnT 15 pg/ml and
5.93 ng/l
n  78
Overall 49%
Men 55%
Women 40%
BNP or hs-cTnT 20 pg/ml or
5.93 ng/l
n  144
Overall 77%
Men 82%
Women 73%
BNP and hs-cTnT 20 pg/ml and
5.93 ng/l
n  42
Overall 40%
Men 47%
Women 40%
NLR  negative likelihood ratio; NPV  negative predictive value; PLR  positive likelihood ratioeldom missed [0% to 7%]) (Fig. 2). ttudy limitations. The main limitation of this study is that
ome forms of cTOD were fairly uncommon in our popu-
ation. The main example is silent ischemia (6.3%), al-
hough the latter still showed a clear increment in frequency
cross the BNP tertiles (i.e., 1% in bottom and middle
ertiles to 17% in top BNP tertile, which agrees overall with
arlier data) (20,21). Intriguingly, the equivalent figures for
s-cTnT were less discriminating at 2%, 8%, and 9% across
he tertiles. Table 3 shows, however, that our results are very
imilar even if we exclude silent ischemia. Another limita-
at Various Cutoff Levels to Identify cTODCombination at Various Cutoff Levels to Identify cTOD
Specificity NPV PPV NLR PLR
51% 87% 50% 0.29 1.7
57% 88% 48% 0.28 2.0
39% 85% 43% 0.17 1.5
65% 79% 55% 0.37 2.6
72% 85% 58% 0.37 2.6
53% 82% 59% 0.36 1.7
78% 76% 61% 0.53 2.6
83% 82% 63% 0.47 3.6
67% 74% 51% 0.61 1.8
90% 70% 66% 0.73 3.4
95% 78% 92% 0.61 8.4
81% 70% 54% 0.77 1.9
55% 81% 55% 0.46 1.7
40% 79% 38% 0.57 1.3
77% 82% 65% 0.36 3.1
75% 74% 51% 0.66 2.0
64% 78% 45% 0.58 1.7
92% 71% 72% 0.71 4.6
40% 90% 43% 0.25 1.5
55% 95% 40% 0.14 1.8
49% 92% 51% 0.16 1.8
83% 80% 74% 0.40 4.0
82% 80% 70% 0.40 3.7
84% 81% 75% 0.38 4.3
48% 86% 50% 0.30 1.7
44% 86% 46% 0.27 1.6
55% 87% 54% 0.27 1.6
90% 77% 71% 0.47 5.8
94% 80% 81% 0.40 10.5
90% 76% 77% 0.47 5.8
65% 90% 66% 0.26 2.4
70% 92% 71% 0.17 2.9
66% 89% 65% 0.22 2.5
92% 75% 70% 0.56 6.0
90% 80% 77% 0.50 5.5
95% 70% 71% 0.63 8.0
67% 88% 67% 0.34 2.3
68% 86% 67% 0.26 2.5
64% 84% 66% 0.42 2.0
95% 81% 77% 0.63 8.0
96% 84% 78% 0.56 11.7
97% 82% 77% 0.62 13.3
positive predictive value; other abbreviations as in Table 1.ationTheir
tyion is that we do not yet have outcome data on our study
c
t
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prevention population found a 3-fold increase in mortality
at the top versus the bottom tertile of N-terminal pro-BNP,
even after adjusting for traditional risk factors (35). Indeed,
the accompanying editorial said that we now need to know
in this population what increases BNP in the absence of
ECG-LVH (37). Our study answers that very question.
Conclusions
Cardiovascular disease and cancer are our main causes of
death, and both often have a pre-symptomatic stage. As a
AUC Values for Various Tests to Identifyny Form of cTOD With or Without IschemiaTable 3 AUC Val es for Various Tests to IdentifyAny Form of cTOD With or Without Ischemia
AUC (95% CI)
Test Cohort
cTOD With
Ischemia
cTOD Without
Ischemia
BNP Overall 0.783 (0.732–0.829) 0.770 (0.721–0.817)
Men 0.818 (0.749–0.888) 0.803 (0.740–0.881)
Women 0.715 (0.625–0.805) 0.703 (0.611–0.795)
hs-cTnT Overall 0.701 (0.630–0.767) 0.686 (0.621–0.751)
Men 0.680 (0.664–0.768) 0.687 (0.601–0.774)
Women 0.754 (0.661–0.847) 0.729 (0.633–0.826)
BNP  hs-cTnT Overall 0.810 (0.759–0.860) 0.802 (0.750–0.855)
Men 0.824 (0.756–0.892) 0.825 (0.759–0.894)
Women 0.787 (0.707–0.868) 0.766 (0.682–0.850)
Major ECG
changes
Overall 0.552 (0.480–0.625) 0.550 (0.478–0.626)
Men 0.539 (0.444–0.635) 0.535 (0.450–0.645)
Women 0.570 (0.457–0.683) 0.555 (0.446–0.665)
Minor or major
ECG changes
Overall 0.614 (0.546–0.683) 0.603 (0.533–0.673)
Men 0.636 (0.546–0.725) 0.624 (0.534–0.714)
Women 0.582 (0.473–0.689) 0.569 (0.463–0.675)
eGFR Overall 0.581 (0.525–0.658) 0.566 (0.507–0.664)
Men 0.614 (0.527–0.699) 0.602 (0.520–0.690)
Women 0.557 (0.454–0.660) 0.552 (0.447–0.657)
Uric acid Overall 0.498 (0.355–0.602) 0.535 (0.461–0.609)
Men 0.497 (0.403–0.592) 0.519 (0.409–0.673)
Women 0.523 (0.447–0.608) 0.523 (0.426–0.611)
Microalbuminuria
(UACR)
Overall 0.611 (0.535–0.678) 0.594 (0.520–0.667)
Men 0.633 (0.540–0.726) 0.626 (0.533–0.720)
Women 0.571 (0.457–0.684) 0.551 (0.438–0.664)
AUC  area under curve; CI  confidence interval; other abbreviations as in Table 1.
Incremental Contribution of Addition of BNP andcTnT to AUC f r CV R sk Scores t Identify cTODTable 4 Inc emental Contribution of Addition of BNP andcTnT to AUC for CV Risk Scores to Identify cTOD
Combination Difference in AUC* z-Statistics p Value
Framingham and BNP 0.1777 (0.104–0.250) 4.574 0.001
Framingham and BNP
and cTnT
0.204 (0.130–0.277) 5.447 0.001
QRISK and BNP 0.191 (0.116–0.265) 5.008 0.001
QRISK and BNP and cTnT 0.217 (0.142–0.291) 5.695 0.001
ASSIGN and BNP 0.168 (0.095–0.241) 4.513 0.001
ASSIGN and BNP
and cTnT
0.194 (0.124–0.264) 5.425 0.001
*Difference between AUC for the cardiovascular (CV) risk scores alone and the combination of CV
risk scores and biomarker(s).
Abbreviations as in Tables 1 and 3.result, screening programs have been developed to identify
early target organ disease in cancer, but such screening
programs for target organ disease do not yet exist in
cardiology, even though sudden death can occur in the
pre-symptomatic stage of heart disease. However, BNP 
cTnT screening now seems to be able to identify those who
already have silent cTOD in a treated population of primary
prevention patients with similar accuracy to other com-
monly used screening tests, such as those for cancer.
Furthermore, the cases missed are seldom the more serious
forms of cTOD (i.e., those with LVSD or ischemia or 2
TODs). If our results are confirmed, this could lead to
rials of adding BNP ( hs-cTnT) screening plus targeted
phenotyping to primary prevention to see whether it really
can deliver better primary prevention of CV events in a
cost-effective way. If so, this could one day propel screening
for pre-symptomatic CV disease into the same league as
screening for certain cancers achieved long ago.
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